

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CHENG ET AL.

APPLICATION NO: 10/616,365

FILED: JULY 8, 2003

FOR: SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS

ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD

MAIL STOP: _______ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the documents cited on the attached form(s) PTO-1449.

Copies of these documents are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each document was considered by returning a copy of the initialed PTO 1449 form(s).

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4336

Date: 10/29/03

Respectfully submitted,

Burton Rodney Attorney for Applicants

Reg. No. 22,076

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Usage vere) sheets if necessary)

ATTY. DOCKET NO. LA0089 NP APPLICATION NO. 10/616,365 APPLICANT CHENG ET AL. FILING DATE JULY 8, 2003

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	***	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,414,002	7/2/02	Cheng et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	АН						
	AI						
	AJ						,
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
AM	0 520 723	6/1/94	EP				
AN	WO 92/22533	12/23/92	PCT				
 AO	WO 95/18130	7/6/95	PCT				
AP	WO 96/38415	12/5/96	PCT				
AQ	WO 97/00258	1/3/97	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Cobb, J.E. et al., "N-(2-BenzoyIphenyl)-L-tyrosine PPAR Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent", J. Med. Chem., Vol. 41, pp. 5055-5069 (1998)
 AS	Collins, J.L. et al., "N-(2-Benzoylphenyl)-L-tyrosine PPAR _γ Agonists. 2. Structure-Activity Relationship and Optimization of the Phenyl Alkyl Ether Moiety", J. Med. Chem., Vol. 41, pp. 5037-5054 (1998)
AT	Henke, B.R. et al., "N-(2-Benzoylphenyl)-L-tyrosine PPAR p Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents", J. Med. Chem., Vol. 41, pp. 5020-5036 (1998)

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

SINFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. LA0089 NP APPLICATION NO. 10/616,365 APPLICANT CHENG ET AL. FILING DATE JULY 8, 2003

Group

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS		SLATION
2AA	WO 97/27847	8/7/97	PCT		S	YES	NO
2AB	WO 97/27857	8/7/97	PCT				
2AC	WO 97/28137	8/7/97	PCT				
2AD	WO 97/28149	8/7/97	PCT				
2AE	WO 97/31907	9/4/97	PCT				
2AF	WO 98/00137	1/8/98	PCT				
2AG	WO 98/00403	1/8/98	PCT				
· 2AH	WO 98/27974	7/2/98	PCT				
2AI	WO 99/07357	2/18/99	PCT				
2AJ	WO 99/08501	2/25/99	PCT				
2AK	WO 99/11255	3/11/99	PCT				
2AL	WO 99/15520	4/1/99	PCT				
2AM	WO 99/16758	4/8/99	PCT				
2AN	WO 99/16770	4/8/99	PCT				
2AO	WO 99/20275	4/29/99	PCT				
2AP	WO 99/46232	9/16/99	PCT				
2AQ	WO 00/08002	2/17/00	PCT				
2AR	WO 00/64876	11/2/00	PCT				
2AS	WO 00/64888	11/2/00	PCT				
2AT	WO 01/38325	5/31/01	PCT				
AU							
AV							
AW		, , , , , , , , , , , , , , , , , , ,					
AX							
AY							
AZ				<u> </u>			
EXAMINER		1	DATE CONSIDERED	. 1		1	

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.